FINWIRES · TerminalLIVE
FINWIRES

$ONCY

5 stories mentioning ONCYUpdated just now

Every FINWIRES story that references ONCY, newest first.

Sectors

Sector Update: Healthcare Stocks Ease Late Afternoon

Healthcare stocks eased late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) also dropped 0.2%.In corporate news, Eli Lilly (LLY) acquired 4E Therapeutics, a neuroscience firm creating chronic-pain treatments. Lilly shares fell 1%.CAMP4 Therapeutics (CAMP) shares jumped 6.1% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares eased 0.1%.Oncolytics Biotech (ONCY) shares climbed 11% after the company received a US patent covering the pelareorep manufacturing process into 2044.

$CAMP$GSK$LLY$ONCY
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly (LLY) submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech (ONCY) shares jumped past 10% after it said Tuesday it has received a US patent covering the pelareorep manufacturing process into 2044.

$GSK$LLY$NVO$ONCY
Sectors

Sector Update: Healthcare

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index increasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) was shedding 0.3%.In corporate news, Oncolytics Biotech (ONCY) shares jumped past 9% after it said Tuesday it has received a US patent covering the pelareorep manufacturing process into 2044.

$ONCY
Wire

Oncolytics Says Preclinical Results Back Further Evaluation of Pelareorep Plus RAS-Targeted Approaches

Oncolytics Biotech (ONCY) said Monday that initial results from a preclinical study assessing pelareorep plus RAS inhibitor modalities in a solid tumor model showed evidence of the combination's greater anti-tumor activity than with the individual approaches alone.The company said that, based on the results, it is planning further studies in models of pancreatic ductal adenocarcinoma and colorectal cancer to further assess the combinations' anti-tumor and immune effects.Full results from the initial preclinical studies are slated to be presented in the fall or winter of this year, Oncolytics said.The company's shares were up more than 8% in Monday premarket trading.

$ONCY
Wire

Oncolytics Biotech Aligns With FDA on Study Design for Pelareorep in Anal Cancer

Oncolytics Biotech (ONCY) said Monday a meeting with the US Food and Drug Administration has led to agreement on how to design a trial to support approval of pelareorep for patients with unresectable metastatic squamous cell carcinoma of the anal canal.The company added that it will use the regulator's feedback to finalize the study plan. The trial is expected to be a single randomized controlled study that could support both accelerated approval and full approval at different stages, the company said.Price: $1.07, Change: $+0.04, Percent Change: +3.88%

$ONCY

Track with the FINWIRES app suite

FolioX
FolioX
Track ONCY in your portfolio
WheelAI
WheelAI
Analyze ONCY options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ONCY